Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health Inc (NYSE: EVH) delivers transformative healthcare solutions through value-based care models and AI-powered technology. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping modern care delivery.
Access authoritative coverage of EVH's strategic initiatives including specialty care management advancements, AI-driven clinical review systems, and partnerships with major health systems. Our curated news collection features earnings reports, regulatory filings, and analysis of operational milestones in oncology, cardiology, and musculoskeletal care management.
Key focus areas include updates on Evolent's proprietary platforms for total cost of care optimization, health plan administration innovations, and value-based payment model expansions. Stay informed about technological integrations like the Machinify Auth AI system that streamline clinical decision-making processes.
Bookmark this page for real-time updates on EVH's progress in aligning financial incentives with patient outcomes. Monitor how their integrated approach to population health management continues to redefine care delivery standards across healthcare networks.
Evolent Health, Inc. (NYSE: EVH) announced that CFO John Johnson will lead a panel titled "Evolent Health Spotlight: New Century Health - Oncology Care Reimagined" on November 18, 2021, from 12-1 pm ET. The panel will include physicians from New Century Health, a subsidiary of Evolent, and partners discussing advancements in oncology care. Interested participants can register and access the event's live webcast via the company's website. The session will last approximately 60 minutes, including a Q&A segment. A replay will be available on the investor relations page afterward.
Evolent Health (NYSE: EVH) announced that CEO Seth Blackley and CFO John Johnson will attend the Piper Sandler 33rd Annual Healthcare Conference on December 1, 2021. The company specializes in clinical and administrative solutions aimed at enhancing health care quality while reducing costs. Evolent is recognized for its innovative contributions to population health management and has received national accolades for its workplace environment. For more information, visit evolenthealth.com.
Evolent Health (NYSE: EVH) announced a partnership with Health New England to provide advanced care planning services via its subsidiary, New Century Health. The initiative, utilizing the Vital Decisions platform, aims to support Health New England's 180,000 members in articulating their healthcare preferences during serious illness. Through personalized consultations, the Living Well program allows patients to document their care goals, ensuring that their choices are reflected in medical plans. This partnership seeks to empower patients and enhance their healthcare experience.
Evolent Health (NYSE: EVH) announces the appointment of Dr. Tunde Sotunde to its Board of Directors, bringing over 20 years of healthcare experience. Dr. Sotunde, currently CEO of Blue Cross and Blue Shield of North Carolina, replaces Michael D'Amato, who is retiring. His leadership at Anthem, where he oversaw Medicaid efforts serving 7.3 million members and generating $33 billion in revenue, underscores his expertise. Additionally, effective January 1, 2022, Frank Williams transitions from Executive Chairman to non-executive Chairman, reflecting the company's governance evolution.
Evolent Health, Inc. (NYSE: EVH) reported third-quarter 2021 financial results, revealing GAAP revenue of $222.5 million, a 7.1% decrease from the previous year. Excluding divested assets, revenue grew 36.3%. The net loss for common shareholders was $(13.0) million, with an adjusted EBITDA of $13.8 million. Total lives managed reached 14.7 million. The company announced new partnerships, exceeding its target of ten for 2021. Full year revenue guidance is revised to $884-$900 million, with adjusted EBITDA expected between $56-$60 million.
Evolent Health (NYSE: EVH) will announce its third quarter 2021 operating results on November 3, 2021, after market close. A conference call is scheduled for 5:30 p.m. Eastern Time the same day. Interested participants can join by calling 855.940.9467 or 412.317.6034 for international listeners, mentioning the "Evolent Health call" 15 minutes prior. The call will also be available for playback on Evolent's investor relations website for a week post-call. Evolent Health specializes in health care solutions aimed at improving affordability and simplifying care delivery.
On October 6, 2021, WindRose Health Investors announced the sale of Vital Decisions, a provider of technology-enabled advance care-planning services, to Evolent Health (NYSE: EVH). This acquisition positions Vital Decisions under Evolent's specialty management division, New Century Health, thus integrating into Evolent’s Clinical Solutions segment. Vital Decisions aims to ensure individuals' healthcare aligns with their values using advanced methodologies and analytics. WindRose had partnered with Vital Decisions since 2012, resulting in significant growth.
Evolent Health, Inc. (NYSE: EVH) announced participation in upcoming investor conferences by CEO Seth Blackley and CFO John Johnson. They will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 3:30 p.m. ET, with a live webcast available on Evolent's website. Additionally, they will present at the 2021 Cantor Global Healthcare Conference on September 27, 2021, at 9:20 a.m. ET. Evolent is known for delivering clinical and administrative solutions that improve health care efficiency and affordability.
Evolent Health, Inc. (NYSE: EVH) announced its acquisition of Vital Decisions from WindRose Health Investors for $85 million, with potential earn-outs up to $45 million. This strategic acquisition aims to integrate Vital Decisions' technology-enabled advance care planning services into Evolent's Clinical Solutions segment, enhancing patient engagement and care alignment. The deal is expected to provide significant clinical and financial synergies while being accretive to EBITDA per share. The transaction is projected to close later this year, pending regulatory approvals.
Evolent Health, Inc. (NYSE: EVH) reported financial results for Q2 2021, achieving GAAP revenue of $222.1 million, a 2.2% increase year-over-year. Organic revenue growth was notably high at 42.3%. However, the company recorded a net loss of $(9.1) million. Adjusted EBITDA rose to $13.3 million, up $2.8 million from Q2 2020. Evolent announced key acquisitions and partnerships that reflect a strategic push for growth, including the acquisition of Vital Decisions. The company also raised its full-year revenue guidance to $870-$900 million.
